CICAB Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain.
Eur J Clin Pharmacol. 2012 May;68(5):637-44. doi: 10.1007/s00228-011-1147-8. Epub 2011 Nov 15.
Cytochrome P450 2D6 (CYP2D6) genotypes and the dextromethorphan/dextrorphan (DXM/DXT) metabolic ratio (MR), which is a marker of CYP2D6 activity, were studied in 118 unrelated healthy Ecuadorians.
Genotyping of CYP2D6 was performed by amplification of entire CYP2D6 gene by XL-PCR for CYP2D6*5 and multiplication alleles and by real time-PCR for CYP2D6 *2, *3, *4, *6, *10, *17, *29, *35, *41, and copy number. The plasma levels of DXM and its metabolite DXT were determined on a high-performance liquid chromatography-UV system.
The proportions of non-functional alleles were 0.4, 10.6, 0.8, 2.1, and 0% for CYP2D6*3, *4, *4 × N, *5, and *6, respectively. Genotypically, only one of the subjects (0.9%) was homozygous for two inactive alleles and phenotypically classified as a poor metabolizer (PM). The MRs (mean ± standard deviation) corresponding to "activity scores" of 0, 0.5, 1, 1.5, 2, and 2.5 were 10.57 (n = 1), 1.63 ± 0.35 (n = 2), 1.16 ± 0.74 (n = 29), 1.00 ± 0.47 (n = 8), 1.24 ± 0.82 (n = 76), and 1.30 ± 0.32 (n = 2), respectively.
Our data suggest that only 1% of subjects of this Ecuadorian population were PMs and that none were phenotypically ultrarapid metabolizers, which is in agreement with previous findings in other Amerindian populations.
研究了 118 名无亲缘关系的厄瓜多尔健康个体的细胞色素 P450 2D6(CYP2D6)基因型和右美沙芬/右啡烷(DXM/DXT)代谢比(MR),后者是 CYP2D6 活性的标志物。
通过 XL-PCR 对 CYP2D65 和乘法等位基因进行 CYP2D6 全长基因扩增,通过实时 PCR 对 CYP2D62、*3、*4、*6、*10、*17、*29、*35、*41 和拷贝数进行 CYP2D6 基因分型。采用高效液相色谱-紫外系统测定 DXM 及其代谢物 DXT 的血浆水平。
CYP2D6*3、*4、*4×N、5 和6 的无功能等位基因比例分别为 0.4、10.6、0.8、2.1 和 0%。在基因型上,只有 1 名受试者(0.9%)为两个无活性等位基因的纯合子,表型上被归类为弱代谢者(PM)。与“活性评分”为 0、0.5、1、1.5、2 和 2.5 对应的 MR(平均值±标准差)分别为 10.57(n=1)、1.63±0.35(n=2)、1.16±0.74(n=29)、1.00±0.47(n=8)、1.24±0.82(n=76)和 1.30±0.32(n=2)。
我们的数据表明,厄瓜多尔人群中只有 1%的受试者为 PM,且无一例为表型超快代谢者,这与其他美洲印第安人群体的先前发现一致。